FDA Grants Priority Review for Genentech’s At-Home Thyroid Eye Disease Treatment
Event summary
- FDA granted priority review to Genentech’s sBLA for Enspryng (satralizumab) as an at-home treatment for thyroid eye disease (TED).
- Decision expected by October 15, 2026, following positive Phase III SatraGO trial results.
- Enspryng demonstrated significant reduction in proptosis (bulging eyes) and other TED symptoms compared to placebo.
- No new safety signals identified; safety profile consistent with its use in neuromyelitis optica spectrum disorder (NMOSD).
The big picture
Genentech’s Enspryng represents a strategic pivot into the rare disease space with an innovative, patient-friendly treatment option. The priority review underscores the FDA’s focus on advancing therapies for debilitating conditions like TED, while Genentech aims to leverage its expertise in autoimmune diseases to expand its portfolio beyond NMOSD.
What we're watching
- Regulatory Approval
- Whether the FDA will approve Enspryng by the October 15, 2026 deadline.
- Market Expansion
- How Genentech plans to position Enspryng in the TED market alongside its existing NMOSD indication.
- Competitive Dynamics
- The potential impact of Enspryng’s at-home administration on competing TED treatments.
Related topics